This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Phosphatidylinositol-4 phosphate 5-kinase type 1 α (PIP5K1A)	<p>Studies in mice and in human tissue samples suggest inhibiting PIP5K1A could help treat prostate cancer. In human samples from patients with prostate cancer, levels of PIP5K1A and its product, phosphatidylinositol 4,5-bisphosphate (PIP₂), were higher than those in samples from patients with benign prostate hyperplasia. In a mouse model of human prostate cancer, a 1,2,3,4-tetrahydroisoquinoline derivative inhibited expression of <i>PIP5K1A</i> and decreased tumor growth compared with vehicle. Next steps include measuring <i>PIP5K1A</i> expression in a larger sample collection including primary tumors and bone metastatic lesions and further understanding the inhibitor's mechanism of action.</p> <p>SciBX 7(34); doi:10.1038/scibx.2014.1011 Published online Sept. 4, 2014</p>	Patent granted covering the inhibitor; licensing status undisclosed	<p>Semenas, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 28, 2014; doi:10.1073/pnas.1405801111</p> <p>Contact: Jenny L. Persson, Lund University, Lund, Sweden e-mail: jenny_l.persson@med.lu.se</p>